Comparing of Zynerba Pharmaceuticals Inc. (ZYNE) and Enochian Biosciences Inc. (NASDAQ:ENOB)

This is therefore a comparing of the profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation in Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) and Enochian Biosciences Inc. (NASDAQ:ENOB). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zynerba Pharmaceuticals Inc. N/A 3191.35 36.75M -2.27 0.00
Enochian Biosciences Inc. N/A 0.00 29.89M -0.82 0.00

Table 1 highlights Zynerba Pharmaceuticals Inc. and Enochian Biosciences Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 represents Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) and Enochian Biosciences Inc. (NASDAQ:ENOB)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zynerba Pharmaceuticals Inc. 0.00% -64.1% -54.9%
Enochian Biosciences Inc. 0.00% -18.7% -16.7%

Volatility and Risk

Zynerba Pharmaceuticals Inc. is 456.00% more volatile than S&P 500 because the company has a beta of 5.56. Enochian Biosciences Inc.’s 38.00% less volatile than S&P 500 which is a result of the 0.62 beta.

Liquidity

The current Quick Ratio of Zynerba Pharmaceuticals Inc. is 9.9 while its Current Ratio is 9.9. Meanwhile, Enochian Biosciences Inc. has a Current Ratio of 8.1 while its Quick Ratio is 8.1. Zynerba Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Enochian Biosciences Inc.

Analyst Ratings

The following table delivered below contains the ratings and recommendations for Zynerba Pharmaceuticals Inc. and Enochian Biosciences Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Zynerba Pharmaceuticals Inc. 0 0 1 3.00
Enochian Biosciences Inc. 0 0 0 0.00

Zynerba Pharmaceuticals Inc.’s upside potential is 38.14% at a $18 average target price.

Institutional and Insider Ownership

The shares of both Zynerba Pharmaceuticals Inc. and Enochian Biosciences Inc. are owned by institutional investors at 13.7% and 1.6% respectively. Insiders held roughly 0.9% of Zynerba Pharmaceuticals Inc.’s shares. Comparatively, Enochian Biosciences Inc. has 0.1% of it’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Zynerba Pharmaceuticals Inc. 13.82% 66.71% 156.35% 133.95% 47.46% 368.69%
Enochian Biosciences Inc. -3.88% -12.95% -22.78% -19.79% 22.68% -16.93%

For the past year Zynerba Pharmaceuticals Inc. had bullish trend while Enochian Biosciences Inc. had bearish trend.

Zynerba Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates include ZYN002, which is in Phase II clinical trial for adult patients with refractory epileptic focal seizures and osteoarthritis, as well as pediatric patients with fragile X syndrome; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.

Enochian Biosciences Inc., a biopharmaceutical company, identifies, develops, manufactures, and commercializes gene therapies for HIV/AIDS and cancer patients. Its lead candidate include ENO-1001 a genetically modified cell therapy for patients with HIV/AIDS. It is also developing ENO-2001, an HIV vaccine; and additional compounds, such as ENO-4001, ENO-4002, ENO-3001, and ENO-5001 that are in discovery stage for prevention of relapse in colon cancer patients. Enochian BioSciences is headquartered in Los Angeles, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.